Skip to main content
HCPCS Q5117 · Level II · Part B drug

HCPCS Q5117: Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for Q5117

Billing unit
10 MG
Inj., kanjinti, 10 mg
ASP payment limit
$63.871
October 2026; +5.5% vs July 2026
Practitioner MUE
120
MAI 3
OPPS status
SI K
APC 9330
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q5117 is the Level II code for Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $63.871 per billing unit, up 5.5% from July 2026. The practitioner MUE allows up to 120 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 9330. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. The ASP crosswalk maps 5 NDCs to it, sold as Kanjinti, Kanjinti (Kit) by Amgen Inc. No current Billing and Coding Article lists Q5117, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5117 at $63.871 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $60.522 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5117
QuarterPayment limitPerCoinsurance
October 2026$63.87110 MG20%
July 2026$60.52210 MG—
CMS note: 8% of reference add-on applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 5 NDCs from 1 labeler to Q5117. Report the NDC in the claim's drug segment and bill the number of Q5117 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to Q5117
NDCDrug nameLabelerPackage sizeBilling units / package
55513-0132-01KanjintiAmgen Inc1 × 142
55513-0132-21KanjintiAmgen Inc1 × 142
55513-0141-01KanjintiAmgen Inc1 × 115
55513-0141-21KanjintiAmgen Inc1 × 115
55513-0164-01Kanjinti (Kit)Amgen Inc1 × 142

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q5117. For practitioners the limit is 120 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5117 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1203 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1203 Date of Service Edit: ClinicalPrescribing Information

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5117 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

Q5117 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q5117 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, Q5117 carries status indicator K and is assigned to APC 9330, with a published national unadjusted payment of $60.52. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for Q5117 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks Q5117 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS Q5117

What does HCPCS code Q5117 describe?

Q5117 is defined by CMS as "Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for Q5117 in October 2026?

The ASP-based payment limit is $63.871 per 10 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $60.522.

How many units of Q5117 can be billed per day?

The practitioner Medically Unlikely Edit is 120 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5117?

The October 2026 ASP crosswalk lists 5 NDCs from 1 labeler: Kanjinti (Amgen Inc); Kanjinti (Kit) (Amgen Inc). For example NDC 55513-0132-01 is a 1 package equal to 42 billing units. The crosswalk's billing-units-per-package figure converts each package into Q5117 units.

Does Q5117 have NCCI bundling edits?

No active practitioner PTP pairs list Q5117 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.